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Abstract
To assess public attitudes and interest in pharmacogenetic (PGx) testing, we conducted a random-
digit-dial telephone survey of U.S. adults, achieving a response rate of 42% (n=1139). Most 
respondents expressed interest in PGx testing to predict mild or serious side effects (73% ±3.29% 
and 85% ±2.91%, respectively), guide dosing (91%) and assist with drug selection (92%). 
Younger individuals (ages 18–34) were more likely to be interested in PGx testing to predict 
serious side effects (vs. ages 55+), as well as Whites, those with a college degree, and who had 
experienced side effects from medications. However, most respondents (78% ±3.14%) were not 
likely to have a PGx test if there was a risk that their DNA sample or test result could be shared 
without their permission. Given differences in interest among some groups, providers should 
clearly discuss the purpose of testing, alternative testing options (if available), and policies to 
protect patient privacy and confidentiality.
Pharmacogenetic (PGx) testing can potentially reduce adverse drug responses and improve 
efficacy of drug treatment. PGx testing may measure either inherited or acquired genetic 
variation and inform drug selection and/or dosage. For example, testing for polymorphisms 
in two genes, VKORC1 and CYP2C9, can inform initial dosage of warfarin, one of the most 
commonly prescribed drugs in the world and one with a narrow therapeutic window.1 While 
it is estimated that about one-fourth of outpatients are taking medications with PGx 
information in their labels,2 only a few require or recommend testing prior to drug use.2, 3
Several studies have assessed general public interest in disease susceptibility genetic testing,
4–9 though only a handful of studies have assessed the public’s perspectives of PGx testing, 
most of which have been on European populations. For example, studies from Germany and 
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the U.K. report that the public are generally supportive of PGx testing but expressed 
concerns regarding patient sovereignty, the unavailability of suitable drugs based on genetic 
make-up, and privacy.10, 11 Participants of an Iceland study were concerned that 
genetically tailored drugs would be more costly and result in greater health disparities.12 It 
is uncertain whether differences in the healthcare systems and coverage and reimbursement 
as well as concerns about genetic discrimination between the U.S. and Europe would yield 
differences in public support for PGx testing in the U.S.
The saliency of these issues were partially confirmed in three focus group studies conducted 
in the U.S. explored public attitudes toward PGx testing within the framework of drugs 
targeted to a patient’s race.13–15 One study found that participants preferred individualized 
genetic testing versus race-based medications, but raised concerns about cost, privacy, and 
discrimination.14 In the other two, participants were likely to be highly suspicious of the 
safety and efficacy of race-based drugs.13, 15 A phone survey of 1,796 Americans reported 
that the public was generally supportive and interested in participating in genetics research, 
including PGx research, but had conflicting views regarding affordability of targeted drugs.
16
Due to the limited understanding of interest in PGx testing among Americans, we conducted 
an anonymous, random-digit-dial telephone survey of a sample of the U.S. public. This 
survey ascertained the public’s views about PGx testing (e.g., knowledge of risks and 
specific uses of PGx tests and how demographics influence their interest in PGx testing). In 
particular, we examined the public’s interest in PGx testing given three potential risks (DNA 
sample could be accessed without patient permission, test result could be accessed without 
patient permission, testing requires a blood draw) and five distinct uses (to predict risk of 
mild side effects, to predict risk of serious side effects, to understand side effects in self or 
family members, to select most effective drug to treat illness, or to select appropriate dose or 
strength) of PGx testing. Past studies have not distinguished between different purposes of 
PGx testing; we believed it would be informative to learn whether interest varied by the 
purposes of testing and if such interest was influenced by personal characteristics, 
familiarity with genetic testing or history of medication side effects as previously 
demonstrated.17 Furthermore, we were interested in identifying subpopulations of 
respondents with lower interest in PGx testing which may warrant further study to 
understand their concerns, to limit disparities in the use of testing with demonstrated 
benefits, and maximize benefits of testing. These data can help identify potential challenges 




Development of the survey involved a collaborative effort between investigators at Duke 
University’s Institute for Genome Sciences & Policy (IGSP) and the Survey Research Unit 
(SRU) at the University of North Carolina, Chapel Hill. The content was based on data 
collected from a series of focus groups, a literature review, and a legal analysis of managing 
incidental findings from PGx testing. IGSP investigators convened four focus groups of the 
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general public to ascertain perceptions and attitudes about PGx testing, and specifically 
about ancillary information resulting from PGx testing. Forty-five individuals recruited from 
Durham, North Carolina participated in the focus groups; members were predominantly 
African-American females, median age range 40–49 years, with a Bachelor’s or graduate 
degree. A hypothetical vignette was used to illustrate potential clinical and ethical issues that 
may arise with PGx testing, particularly regarding ancillary information. The discussion was 
structured so as to guide participants toward formulation of informed opinions and to elicit 
the reasons underlying their opinions. Although not nationally representative, the focus 
groups served to increase our understanding of public attitudes toward PGx testing and 
inform the creation of the survey to incorporate issues important to the public along with 
other issues identified in the published literature.
Survey Pilot
The SRU conducted a pretest between the 9th and 16th of August 2009 with 52 North 
Carolina residents. The purpose of the pretest was to evaluate the quality of the computer-
assisted telephone interviewing (CATI) programming; ii) appropriateness of the survey 
content for telephone administration; and iii) quality of the survey data. The sampling frame 
consisted of 500 randomly selected telephone numbers in North Carolina purchased from 
GENESYS Sampling Systems (Fort Washington, PA). Adults 18 years of age or older were 
eligible to participate in the survey. Behavioral coding18 was conducted during the pilot 
survey to identify potential problems with survey items as well as documenting other 
administration barriers. Revisions to the survey were made to minimize redundancy, clarify 
intention of questions, and reduce length. The resulting survey was comprised of five major 
parts, totaling 52 questions: 1) demographics; 2) experience with prescription medications; 
3) experience with and awareness of genetic testing; 4) interest in PGx testing given certain 
risks and benefits of testing; and 5) interest in learning of ancillary information revealed by 
PGx testing. Responses to questions regarding management of ancillary findings will be 
published separately.
Sampling methods
A stratified random-digit-dial sample of 20,848 telephone numbers was selected for this 
survey. Stratification was based on the U.S. census regions (West, Mid-West, Northeast, 
South) and included all households with telephone-line access. We achieved an overall 
response rate of 42% (n=1139)19 where telephone numbers were finalized as either non-
response (eligible but no interview; n=1,010), ineligible (non-residential numbers, non-
English speaking households, or emancipated youth households; n=14,335), or unknown 
(eligibility never verified; n=4,364). To be considered eligible, a telephone number needed 
to reach a household with an English-speaking adult resident 18 years of age or older. If 
more than one eligible adult resided in the household, one was selected at random via a 
computer-generated algorithm.
Data Collection
The national survey was conducted from September 17 to November 20, 2009. Calls were 
made every day of the week except Friday between the hours of 9:30am to 12:00am (EST). 
A CATI software package (Blaise 4.6)20 was used to assist interviewers in the 
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administration of the survey and to manage all call attempts. No telephone numbers were 
removed from calling until a minimum of 12 unsuccessful call attempts were made and at 
least one weekend, evening, and daytime call was made. Interviewers completed general and 
project-specific training before conducting the surveys. Interviews lasted approximately 13 
minutes. For quality control, all interviewers were monitored periodically and written 
feedback was provided to them biweekly. This study was approved by the Institutional 
Review Boards at Duke University Medical Center and the University of North Carolina, 
Chapel Hill.
Data Analysis
Though random selection procedures were used within households, the respondents who 
completed the survey (n=1,139) tended to be older, White, and female, to a greater extent 
than would be expected by chance alone (see Table 1). To correct for such sample 
imbalances and reduce the potential effects of bias, the survey data were adjusted by age 
(18–34, 35–54, 55 years and older), race (White, non-White), and gender (male, female) 
according to normative data from the American Community Survey.21 The majority of 
questions had answer options based on a 4-point Likert scale that measured respondent’s 
levels of either likelihood, interest or, comfort relative to certain scenarios. For the purposes 
of statistical analysis, the answer choices were dichotomized into “likely”, which included 
“most likely” and “somewhat likely”, and “unlikely”, which included “most unlikely” and 
“somewhat unlikely”. Analysis primarily consisted of logistic regressions by which model 
building was based on hypothetically related covariates with adjustment for demographic 
characteristics; final variable selection was conducted using the backward selection 
approach. Odds ratios and corresponding 95% confidence intervals were then computed, 
using a significance level of 5% for all statistical tests. Cochran-Mantel-Haenszel (CMH) 
tests adjusted for four control variables (sex, age group, level of education, race) and were 
applied when comparing two groups on a binary response. All analyses were conducted in 
SAS (Version 9.1.3 using Proc Frequency, Proc Logistic & Proc Regression).
RESULTS
Respondent Characteristics
Respondents were 51% female, between 34–55 years (38%), and predominantly White 
(78%) (Table 1). Almost all respondents had some type of health insurance (86%), mostly 
provided through their employer (74%), and 62% were employed. Seventy-nine percent of 
respondents characterized their health status as excellent or good, which is comparable to 
national reports of self-rated health status.22 Forty-seven percent of respondents had 
experienced a side effect from a prescription drug; of those, 80% had stopped taking the 
drug. Overall, 36% had stopped taking a drug due to ineffectiveness, of their own accord or 
based on physician orders.
Awareness/Experience with Genetic Testing
Eighty percent of respondents heard of genetic testing. Overall, 14% (±2.80%) of 
respondents indicated they or a family member had had a disease-related genetic test 
performed. A few respondents indicated their physician had ordered a PGx test for them (1% 
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±0.76%) or a family member (4% ±1.70%) to predict drug response. As shown in Table 2, 
awareness of genetic testing was associated with several factors including gender (women), 
race (White), a college degree, and good or excellent self-rated health status. Those over the 
age of 54 were less likely to have heard of genetic testing as compared to those between the 
ages of 18–34.
Of those that had heard of genetic testing, 54% (±4.30%) reported that they understood its 
healthcare application ‘very well’ or ‘somewhat well.’ In contrast to the positive 
associations observed with awareness of genetic testing, women (OR=0.71, p= 0.01, 95% CI 
[0.54, 0.93]) as well as Whites (OR=0.71, p= 0.049, 95% CI [0.50, 0.999]) were less likely 
to report having a good understanding about the use of genetic testing in healthcare. 
However, those with at least a college degree compared to those with less than a college 
degree (OR=1.85, p <0.0001, 95% CI [1.40, 2.46]), as well as those who have a health-
related job versus those who do not (OR=1.50, p=0.03, 95% CI [1.05, 2.15]) were more 
likely to report a good understanding of the uses of genetic testing in healthcare.
Interest in PGx Testing Given Potential Risks and Uses
As information order may influence interest in testing,23–26 we presented general 
information about PGx testing first, followed by three potential risks, and lastly, five 
different uses of PGx testing (i.e., benefits). Respondents were asked their likelihood to have 
testing after learning of each risk or specific use, and then overall, after each set of potential 
risks and test uses were presented. Most respondents were ‘not very’ or ‘not at all’ likely to 
have PGx testing if there was a chance their DNA sample or test result could be shared with 
others without their permission (78% ±3.14% each). A minority would be “not very’ or ‘not 
at all’ likely to have testing if a blood sample was required (23% ±3.25%). In contrast, most 
respondents (70%–92%) expressed interest in PGx testing for the various purposes presented 
(see Figure 1). Using the CMH test, adjusting for sex, age group, level of education, and 
race, the differences between the levels of interest for these questions were found to be 
statistically significant.
Impact of Personal Factors on Interest in PGx Testing
Four factors were found to be significantly associated with interest in testing for two of the 
three risks and intended uses presented: awareness of genetic testing (intended uses only), 
race (risks and intended uses), education (risks only), and personal history of side effects 
(risks only) (see Tables 3 and 4). No independent variables were found to be significantly 
associated with strong interest in PGx tests for two of the uses presented (guiding drug 
selection to optimize effectiveness and dosing) (Table 4).
Respondents who self-identified as White were more likely to have a strong interest in PGx 
testing (“strong” referring to extremely or somewhat likely to have testing) to understand 
why they or a family member experienced side effects or failed to respond to certain drugs 
or despite the risk that the DNA sample could be accessed without the patient’s permission. 
Similarly, Whites were more likely to have a stronger interest in PGx testing to understand 
why they or a family member experienced side effects or failed to respond to certain drugs 
or despite the risk that the DNA sample could be accessed without the patient’s permission. 
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Whites were more likely to have a strong interest in testing to predict risk of serious side 
effects.
Those who had experienced a side effect from a prescribed drug were more likely to have a 
strong interest despite the risk that the DNA sample could be accessed without the patient’s 
permission or the need for a blood test. In addition, respondents who had experienced a side 
effect from a prescribed drug in PGx testing were more likely to have a strong interest in 
testing to understand why they or a family member experienced side effects or failed to 
respond to certain drugs.
Respondents with a college degree had a higher likelihood of having a strong interest in 
testing to predict risk of serious side effects (such as heart failure or seizures) and a lower 
likelihood of having a strong interest in testing to predict risk of mild side effects (such as 
drowsiness, dizziness, or upset stomach). However, respondents familiar with genetic testing 
were more likely to have a strong interest in testing to predict risk of either serious or mild 
side effects.
Overall Interest in PGx Testing
After being informed about the risks, 65% (±3.69%) indicated they would be extremely or 
somewhat likely to have a PGx test. After learning of the uses of PGx testing, interest in 
PGx testing significantly increased to 82% ±3.02% (CMH statistic of general association: 
263.74, p<0.0001).
After learning of some of the risks, the likelihood of having an overall strong interest in PGx 
testing was greater for those with a college degree (OR=1.45, p=0.0145, 95% CI [1.08, 
1.94]) and for respondents who had experienced a side effect with a prescribed drug 
(OR=1.55, p=0.0022, 95% CI [1.17, 2.05]). Women (OR=0.63, p=0.0008, 95% CI [0.476, 
0.822]) were less likely to have PGx testing. However, after learning about the different uses 
of PGx testing, the associations between likelihood of testing and gender and education were 
no longer significant, leaving experience of a side effect as the only factor significantly 
associated with likelihood of testing (OR=1.56, p=0.042, 95% CI [1.02, 2.40]). No 
significance was found between strong interest in PGx testing and age, race, health status, or 
awareness of genetic testing.
For the subset of respondents who indicated they were not very or not at all likely to have a 
PGx test after learning of some risks (35% ±3.69%), we assessed interest in having a non-
genetic test (did not involve analysis of genes) that would provide similar information about 
drug response. Half of the respondents (±6.67%) indicated that they would still be unlikely 
to have a non-genetic test. Compared to respondents aged 18–34 years though, 35–54 year 
olds were more likely to have a non-genetic test in this scenario (OR=1.25, p=0.012, 95% CI 
[0.73, 2.15]) and those aged 55+ were less likely (OR=0.48, p=0.0005, 95% CI [0.278, 
0.841]). In addition, the likelihood of interest in a non-genetic test was greater for those with 
a college degree (OR=2.12, p=0.0023, 95% CI [1.307, 3.424]) and Whites (OR=2.79, 
p=0.0001, 95% CI [1.644, 4.724]). After learning of the uses of PGx testing, 18% were still 
not very or not at likely to have PGx testing; 62% of this indicated that they were not likely 
to have a non-genetic PGx test.
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As PGx testing expands across medical specialties and into primary care, a larger proportion 
of the public will begin to encounter these tests. In addition to demonstrating the clinical 
utility and ensuring coverage of testing, the translation of PGx tests will be influenced by 
patient attitudes and interest. Past surveys have reported favorable support for PGx testing 
and our findings are consistent with these results in a national U.S. sample.
Level of interest in PGx testing is comparable to the generally high interest reported for 
genetic testing for colon cancer5 or hereditary cancers in general4, 6–8 and heart disease.6, 
8, 9 There are conflicting data on the relationship between level of education and attitudes 
toward genetic testing.9, 27–30 Some studies have found an inverse relationship between 
education level and positive attitudes toward genetic testing.9, 28 Others have found that 
individuals knowledgeable about genetic testing have more positive attitudes towards 
testing29 but also may express skepticism.27 Yet other surveys find no evidence to support 
a correlation between knowledge about biotechnology in general and attitudes towards it.31 
Although 20% of respondents in our survey had not heard of genetic testing, we did not 
observe a relationship between overall interest in PGx testing and awareness. However, we 
found that those with less than a college degree had a lower interest in PGx testing after 
being informed of the risks; this association disappeared after they learned about the specific 
uses of testing. Similar to other studies,32 we found greater awareness of genetic testing in 
Whites compared to non-Whites, but race was not associated with overall interest in PGx 
testing.
The order of information presented about genetic testing can affect attitudes toward testing 
with the information presented first being more influential.24 After assessing overall 
interest, we did not find presentation of the risks first as most influential, perhaps due to 
high general interest in genetic testing or familiarity and/or experience with drug side effects 
or non-response. However, when presented with individual risks such as loss of 
confidentiality, only a minority indicated they would be interested in PGx testing. Despite 
the nearly 10-year gap between the two surveys, our findings were comparable to Rothstein 
& Hornung (2003) with respect to interest in PGx testing given concerns about 
confidentiality (78% in our survey vs. 70% in their survey would be less likely to undergo 
PGx testing). As we did not disclose the fact that federal law now prohibits discriminatory 
actions by health insurers or employers (regulations were still pending at the time the survey 
was administered), it is not certain whether knowledge of federal protections would have 
increased interest following presentation of individual risks. Given ongoing concerns, 
disclosure of these policies should be a required element of the discussion about PGx testing 
with patients.
As anticipated, presentation of the different uses of PGx testing boosted interest. We had 
hypothesized that the public would vary in their level of interest of different uses of a PGx 
test as some uses may be considered more important than others, but found little difference. 
Commonalities existed between factors predictive of interest in PGx testing given certain 
risks or intended uses, though no single characteristic was predictive of likelihood, 
suggesting that a combination of personal factors, awareness of genetics, and health and 
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medication history influence interest in PGx testing. The absence of significant differences 
could also be attributed to lack of understanding of the different specific test uses (e.g., 
effectiveness vs. safety). The lack of context or details of a specific treatment scenario may 
have also resulted in generally high interest in all uses. Four factors were significantly 
associated with interest in testing for two of the three risks and intended uses presented: 
awareness of genetic testing, race, education, and personal history of side effects. The lower 
interest in PGx testing by non-Whites given some risks and intended uses may indicate 
differences in perceived harms (higher) and value of the information (lower), potentially 
attributed to mistrust of genetic testing33, 34 or the health system in general, but not strong 
enough to influence overall interest in testing. Interestingly though, race and education were 
not associated with likelihood of testing given risk of loss of confidentiality as reported by 
Rothstein & Hornung (2003). Our finding that history of side effects was linked to overall 
interest confirm previous findings with respect to PGx testing,17, 35 analogous to the higher 
interest in genetic testing in at-risk individuals (i.e., those with a family history).36, 37
Of the minority of respondents that indicated they were initially not very or not at all likely 
to have a PGx test, about half indicated they would be interested in a non-genetic test that 
provided similar information about drug response, suggesting that development of non-
DNA-based PGx tests may help increase uptake. Interest in a non-genetic test was 
associated with higher education status, possibly suggesting greater awareness of potential 
risks of testing. Shields et al.38, 39 reported that primary care physicians would be more 
likely to order a non-genetic test compared to a genetic test to predict response to smoking 
cessation therapy, suggesting some reluctance, either on the part of physicians or their belief 
that their patients would be reluctant to consent to a genetic test. Of our respondents who 
were unlikely to have any testing for drug response, genetic or otherwise, we speculate that 
other concerns not related to ‘genetic testing’ account for their lack of interest in testing. 
Given the long-term benefits of PGx testing over a patient’s lifetime, declining testing could 
have multiple adverse consequences including access to best available therapies if testing is 
required prior to use. Thus, careful consideration must be given to weighing the benefits and 
risks of use of a given treatment if testing is not performed, coverage policies of treatments 
without testing, and alternative approaches to monitoring adverse responses.
Given the sometimes different allele prevalence between populations, it will be essential to 
include as diverse study populations as possible to ascertain PGx associations as well as 
potential physiologic functional differences. Groups with lower interest in PGx testing may 
be less inclined to participate in such studies, creating a significant knowledge gap. On the 
other hand, groups with higher interest in PGx testing, such as individuals with prior 
experience of side effects, may be more interested in participating in PGx research. Careful 
attention should be given to assessing outcomes based on patient self-reporting to minimize 
confounding.
As the clinical evidence basis increases and PGx testing is routinely ordered in the clinic, it 
is critical to ascertain the public’s interest and perceived barriers to this new application. The 
public is strongly supportive of PGx testing, however, their interest is influenced by a 
combination of factors, most notably prior experience with side effects. Although informed 
consent is not usually obtained for PGx tests currently40–42 given the different levels of 
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interest among some groups, providers should discuss the exact purpose of testing, alterative 
testing options (if available), and the protections in place to protect their privacy and 
confidentiality. While the high level of interest in PGx testing is encouraging, public interest 
in genetic testing may not translate to high uptake.43, 44 Patients recommended PGx testing 
in an actual clinical situation may respond differently depending on the circumstances of the 
situation or potential other factors not raised in this study. Thus, clinical studies will be 
needed to assess actual uptake of testing, with a particular focus on patients who are 
declining testing, such as assessing factors that impact patient decisions regarding testing 
such as patient expectations and/or concerns about testing . Based on these data gathered 
from a real-world setting, we will gain a better understanding of the barriers to actual uptake 
or refusal that may inform changes in the delivery of PGx testing, patient communication, 
and application of PGx testing to therapeutic decision-making.
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Likelihood to have PGx testing for certain uses. Using the CMH test, adjusting for sex, age 
group, level of education, and race, the differences between the levels of interest for these 
questions were found to be statistically significant.
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Table 2
Respondent characteristics associated with awareness of genetic testing in general based on multivariate 
logistic regression modeling. The odds ratio (OR) was calculated to reflect the likelihood of awareness of 
genetic testing given respondent characteristics.
Odds Ratio 95% CI p-value
Age Group 2 vs. 1 (35–54 years vs. 18–34 years) 0.81 [0.53, 1.23] 0.07
Age Group 3 vs. 1 (+55 years vs. 18–34 years) 0.35 [0.23, 0.54] <0.0001
Sex (F vs. M) 1.51 [1.10, 2.07] 0.01
Education (At least a college degree vs. Less than a college degree) 1.69 [1.18, 2.42] 0.004
Health Insurance (Insured vs. Not insured) 1.38 [0.88, 2.16] 0.16
Race (White vs. Non-White) 1.74 [1.22, 2.49] 0.002
History of Side Effects (Yes vs. No) 1.81 [1.31, 2.51] 0.0004
*
Unadjusted percentages are weighted to the U.S. population based on data reported by the American Community Survey (2008). This table 
reflects the weighted data.
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Table 3
Multivariate logistic regression model with three potential risks of PGx testing as dependent variables. The 








require a blood draw
Awareness of Genetic testing (Aware vs. Not aware) OR=0.93, p=0.69,95% CI [0.63, 1.35]
OR=0.72, p=0.07,
95% CI [0.50, 1.03]
OR=1.51, p=0.02,
95% CI [1.06, 2.15]
Age Group 2 vs. 1 (35–54 years vs. 18–34 years) OR=0.84, p=0.92,95% CI [0.59, 1.20]
OR=1.00, p=0.91,
95% CI [0.70, 1.43]
OR=0.63, p=0.86,
95% CI [0.43, 0.92]
Age Group 3 vs. 1 (+55 years vs. 18–34 years) OR=0.73, p=0.18,95% CI [0.50, 1.07]
OR=1.03, p=0.84,
95% CI [0.71, 1.51]
OR=0.37, p<0.0001,
95% CI [0.25, 0.56]
Sex (F vs. M) OR=0.75, p=0.06,95% CI [0.56, 1.01]
OR=0.65, p=0.004,
95% CI [0.49, 0.87]
OR=0.76, p=0.07,
95% CI [0.56, 1.02]
Education (At least a college degree vs. Less than a college 
degree)
OR=0.92, p=0.60,
95% CI [0.67, 1.26]
OR=1.17, p=0.32,
95% CI [0.86, 1.61]
OR= 2.30, p<0.0001,
95%CI [1.64, 3.24]
Race (White vs. Non-White) OR=1.53, p=0.03,95% CI [1.04, 2.24]
OR=1.31, p=0.16,
95% CI [0.90, 1.90]
OR=2.03, p<0.0001,
95% CI [1.45, 2.85]
Self-Rated Health Status (Excellent/ Good vs. Fair/Poor) OR=1.19, p=0.38,95% CI [0.81, 1.75]
OR=0.62, p=0.01,
95% CI [0.44, 0.89]
OR=0.82, p=0.31,
95% CI [0.56, 1.20]
Personal History of Side Effects (Yes vs. No) OR=1.37, p=.04,95% CI [1.02, 1.85]
OR=1.13, p=0.43,
95% CI [0.84, 1.52]
OR=1.55, p=0.005,
95% CI [1.14, 2.11]













Haga et al. Page 17
Table 4
Multivariate logistic regression model with three of the five potential benefits of PGx testing presented in the 
survey as dependent variables. No significant associations were observed for use of PGx testing to select most 
effective drug to treat illness or to select appropriate dose or strength. The odds ratio (OR) was calculated to 
reflect the likelihood of having a PGx test given a specific use.
PGx testing used to
predict risk of mild side 
effects
PGx testing used to
predict risk of serious side 
effects
PGx testing used to
understand side effects in self or 
family members
Awareness of Genetic testing 
(Aware vs. Not aware)
OR=1.53, p=0.02,
95% CI [1.09, 2.16]
OR=1.80, p=0.004,
95% CI [1.21, 2.67]
OR=1.42, p=0.10,
95% CI [0.94, 2.16]
Age Group 2 vs. 1 (35–54 years 
vs. 18–34 years)
OR=0.97, p=0.98,
95% CI [0.69, 1.36]
OR=0.98, p=0.26,
95% CI [0.63, 1.53]
OR=1.01, p=0.49,
95% CI [0.65, 1.56]
Age Group 3 vs. 1 (+55 years vs. 
18–34 years)
OR=0.93, p=0.71,
95% CI [0.65, 1.33]
OR=0.627, p=0.02,
95% CI [0.40, 0.98]
OR=0.78, p=0.20,
95% CI [0.50, 1.22]
Sex (F vs. M) OR=0.77, p=0.06,95% CI [0.58, 1.01]
OR=0.91, p=0.60,
95% CI [0.64, 1.29]
OR=0.55, p=0.001,
95% CI [0.38, 0.78]
Education (College degree vs. 
Less than a college degree)
OR=0.68, p=0.01,
95% CI [0.51, 0.91]
OR=2.10, p<0.001,
95% CI [1.38, 3.20]
OR=1.04, p=0.85,
95% CI [0.71, 1.52]
Race (White vs. Non-White) OR=0.84, p=0.33,95% CI [0.59, 1.19]
OR=2.54, p<0.0001,
95% CI [1.74, 3.70]
OR=1.57, p=0.03,
95% CI [1.05, 2.34]
Self-Rated Health Status 
(Excellent/ Good vs. Fair/Poor)
OR=0.65, p=0.03,
95% CI [0.45, 0.95]
OR=1.35, p=0.15,
95% CI [0.89, 2.04]
OR=1.07, p=0.77,
95% CI [0.69, 1.67]
Personal History of Side Effects 
(Yes vs. No)
OR=0.83, p=0.19,
95% CI [0.63, 1.10]
OR=1.28, p=0.18,
95% CI [0.89, 1.85]
OR=1.58, p=0.02,
95% CI [1.10, 2.28]
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